Evidence map›Paper›PMID 39296977›Full record

ArticleFrontiers in oncology2024

Case report: Successful therapy with azacitidine for acute myeloid leukemia with NUP98::RARG resembling acute promyelocytic leukemia.

Zhichen Wei, Linlin Shao, Shuqian Xu, Xiaolin Zhang, Lin Wang, Ping Qin, Qiang Song, Ming Hou, Yan Shi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhichen WeiDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Linlin ShaoDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Shuqian XuDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Xiaolin ZhangDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Lin WangDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Ping QinDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Qiang SongDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Ming HouDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Yan ShiDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of acute myeloid leukemia (AML) with retinoic acid receptor gamma (RARG) rearrangement, exhibiting clinical, morphological, and immunophenotypic features similar to classic acute promyelocytic leukemia (APL). RNA sequencing analysis of the patient's bone marrow samples revealed the presence of nucleoporin 98 (NUP98)-RARG caused by translocation. AML with RARG rearrangement is insensitive to all-trans retinoic acid (ATRA) and arsenic trioxide. The patient received azacitidine therapy after failing ATRA and standard 3 + 7 therapy (idarubicin and cytarabine) and achieved complete remission. Conclusively, this acute myeloid leukemia subtype may benefit from azacitidine.

Indexed as

acute myeloid leukemiaacute promyelocytic leukemiaall-trans retinoic acidazacitidinenucleoporin 98-retinoic acid receptor gamma

Identifiers

PMID39296977
PMCPMC11408469

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.